The Present and FutureJACC State-of-the-Art ReviewRecent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review
JACC State-of-the-Art Review
Under an Elsevier user license
open archive
Central Illustration
Key Words
COVID-19
anticoagulant
antiplatelet
clinical trial
RCT
thrombosis
Abbreviations and Acronyms
BID
twice daily
CI
confidence interval
COVID-19
coronavirus disease-2019
CrCl
creatinine clearance
DOAC
direct oral anticoagulant
HMGB1
high-mobility group box protein 1
ICU
intensive care unit
LMWH
low-molecular-weight heparin
NET
neutrophil extracellular trap
PaO2/FiO2
partial arterial pressure of oxygen/fraction of inspired oxygen
QD
once daily
RCT
randomized controlled trial
SARS-CoV-2
severe acute respiratory syndrome-coronavirus-2
UFH
unfractionated heparin
VTE
venous thromboembolism
WHO
World Health Organization
Cited by (0)
Paul F. Bray, MD, served as Guest Associate Editor for this paper. Christie Ballantyne, MD, served as Guest Editor-in-Chief for this paper.
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center.
© 2021 by the American College of Cardiology Foundation. Published by Elsevier.